AzTrials
AzTrials

Anemia, Iron-DeficiencyPhase 4NCT02631668

the Efficacy and Safety of Vitamin C for Iron Supplementation in Adult IDA Patients

A Phase 4 study testing ferrous succinate and vitamin C and ferrous succinate in people with Anemia, Iron-Deficiency, run by Huashan Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

IDA patients ofen receive ferrous succinate treatment to speed up the recovery of anemia, the doctor will prescribe ferrous succinate with or without vitamin C according to their own preferences. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Anemia, Iron-Deficiency
What is being tested?
ferrous succinate and vitamin C and ferrous succinate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
440 participants
Where
1 siteChina
Study dates
1 Jan 2016to 31 Dec 2018
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Hemoglobin (Hb) < 120 g/L in men and Hb < 110 g/L in women; Mean Corpuscular Volume(MCV) < 80 fl, Mean Corpuscular Hemoglobin(MCH) < 27 pg, and Mean Corpuscular Hemoglobin Concentration(MCHC) < 0.32; the blood biochemical examination: serum ferritin < 12 g/L, serum iron < 8.95 mol/L, transferrin saturation <15%, and total iron binding capacity>64.44 mol/L; with a history of Menorrhagia, monophagia or eating disorders; Willing to sign a Informed consent form.

Who cannot join

  • Pregnant women; drug allergy; the patients with serious gastrorrhagia, other peptic ulcers, active bleeding, hepatic insufficiency, heart disease or renal insufficiency; those patients can't tolerate the medicine orally, or participate in other clinical study, or refuse to sign a Informed consent Form.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Hushan Hospital

    Shanghai, Shanghai Municipality, 200040

Other trials in China

About this study

Official title: The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA)

IDA patients ofen receive ferrous succinate treatment to speed up the recovery of anemia, the doctor will prescribe ferrous succinate with or without vitamin C according to their own preferences. In theory, only the divalent iron can be absorbed in duodenum and upper jejunum, vitamin C can oxidize ferric iron into divalent iron and maintains a certain degree of acidity in the intestine, and then promotes the absorption of iron. In current clinical practice, it's lack of randomized controlled trial(RCT) about the efficacy and safety of vitamin C for iron supplementation in patients with IDA. In this study, the efficacy and safety of vitamin C for iron supplementation in adult IDA patients are explored by RCT. The dosage regimens of ferrous succinate with or without vitamin C are randomly assigned to patients who meet the inclusion criteria, and these patients are followed up every two weeks. On the one hand, whether the addition of vitamin C can accelerate the recovery of anemia is evaluated, on the other hand, whether the addition of vitamin C can increase the incidence of gastrointestinal tract discomfort is aslo appraised , the discomfort include vomiting, nausea, abdominal pain, diarrhea and constipation. We hypothesis that vitamin C can increase the absorption of iron and accelerate the recovery of anemia, it also increases incidence of gastrointestinal adverse events because of increased iron absorption at the same time.

Read the detailed description

BACKGROUND Iron deficiency(ID) causes approximately half of all anemia cases worldwide, a moderate degree of iron-deficiency anemia(IDA) affected approximately 610 million people worldwide or 8.8% of the population. It is slightly more common in female (9.9%) than males (7.8%). In 2013, anemia due to iron deficiency resulted in about 183,000 deaths. IDA is an urgent problem to be solved.

Iron deficiency anemia(IDA) is anemia due to not enough iron. Anemia is defined as a decrease in the amount of red blood cells (RBCs) or hemoglobin in the blood. It is caused by insufficient dietary intake and absorption of iron, or iron loss from bleeding. In babies and adolescents, rapid growth may outpace dietary intake of iron, and result in deficiency without disease or grossly abnormal diet. In women of childbearing age, heavy or long menstrual periods can also cause mild iron-deficiency anemia. Anemia is sometimes treatable, but certain types of anemia may be lifelong. If the cause is dietary iron deficiency, eating more iron-rich foods, such as beans, lentils or red meat, or taking iron supplements will usually correct the anemia.

In clinic, IDA clinically divided into three stages: ID, iron deficiency erythropoiesis (iron deficiency erythropoiesis, IDE) and IDA. The first stage is the reduction of iron storage, and there is a history of inadequate iron absorption; the second stage is the IDE, in addition to iron reduction or lack of external storage, transferrin is also reduced, the intake of iron in red blood cells is reduced compared to normal condition at this time; IDA is the last stage of iron deficiency. If the patients are diagnosed with ID and this condition can be corrected by diet therapy; if it reaches the IDA criteria, it's need to take iron orally and improve symptoms as soon as possible, but the most important is to find the cause of iron deficiency. Ferrous succinate is commonly used to treat IDA in clinic, mainly absorbed in the duodenum and proximal jejunum in the form of ferrous iron. In health people, 5% to 10% of the iron are absorbed after taken orally. the absorption proportion is increased to 20%~30% in IDA patients. After absorbed, ferrous iron can bind to transferrin and enter the blood circulation, and then involve in the production of red blood cells as raw materials. In clinical practice, the doctor will prescribe ferrous succinate with or without vitamin C according to their own preferences. Vitamin C Involves in many biological processes in vivo, such as, collagen formation, tissue repair, the synthesis of phenylalanine, tyrosine, metabolism of folic acid, iron and maintains vascular integrity. Researchers have shown that increased iron intake with vitamin C can prevent anemia,the application of vitamin C can reduce the toxicity symptoms in genotoxic caused by ferric iron, it demonstrates that vitamin C is safe when combined with ferrous succinate. In theory, only the divalent iron can be absorbed in the duodenum and upper jejunum, vitamin C can oxidize ferric iron into divalent iron and maintains a certain degree of acidity in the intestine, and then promotes the absorption of iron. However, the feasibility in theory can not represent the clinical practice. So it's necessary to explore the efficacy and safety of vitamin C for iron supplementation in adult IDA patients through randomized controlled trial(RCT).

PROCEDURE Before the start of this study, the manila envelope is used to carry out the random allocation scheme, different treatment options are randomly loaded into the envelope according to the randomization generated by Stata 11.0 software. In terms of the inclusion criteria, We write the serial number of patients on the envelope after signing informed consent form and give different treatments according to the internal treatment option in envelope. In addition to the above treatment, increased intake of protein, calcium, iron, vitamins and essential fatty acids, appropriate heat are also advised at the same time. In order to check the compliance of the subject, the drug package and aluminum cardboard are asked to return to researchers at follow-up every two weeks, patients should be emphasized that they return all the drug packages, including the pharmaceutical packages that are not taken and run out of, which will help researchers to analyze the patient medication correctly. The number of tablets is to count and determine how much of the remaining drugs and the drugs the patients have taken. During the period of study, patients who participate in this study are not allowed to use other drugs that may affect the effect of iron supplementation. In special circumstances, the patient will be excluded because of using other drugs that affect the absorption of iron or vitamin C. The patients will receive blood routine examination at follow-up every two weeks, the results of examination,the reason and number of termination and loss, the incidence of adverse events in patients, such as, nausea, vomiting, abdominal pain, diarrhea and constipation are all recorded. Finally, we analyze the data to determine the effect and safety of vitamin C for iron supplementation. In this study, we hypothesis that vitamin C can increase the absorption of iron and accelerates the recovery of anemia, it also increases the incidence of gastrointestinal adverse events because of increased iron absorption at the same time.

Being tested
ferrous succinate and vitamin C, ferrous succinate
Keywords
iron deficiency anemia, vitamin C, ferrous succinate
Medical subject headings
Anemia, Iron-Deficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ferrous succinate and vitamin CDrug

    As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time

  • ferrous succinateDrug

    As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice

  • ferrous succinateDrug

    As another active comparator, patients take the tablets of ferrous succinate with double dosage

Study groups in NCT02631668
Study groupRoleWhat they receive
ferrous succinate and vitamin CExperimentalIn this group, the patients received 100mg ferrous succinate and 200mg vitamin C three times per day for 3-4 months
Receives: Drug: ferrous succinate and vitamin C
ferrous succinate with normal dosageActive comparatorIn this group, the patients received 100mg ferrous succinate three times per day for 3-4 months
Receives: Drug: ferrous succinate
ferrous succinate with double dosageActive comparatorIn this group, the patients received 200mg ferrous succinate three times per day for 3-4 months
Receives: Drug: ferrous succinate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hemoglobin

    The increased levels of hemoglobin after receiving three different treatment regimens are evaluated in the second week

    Measured: two weeks

Secondary outcomes (4)
  1. Reticulocyte

    The increased levels of reticulocyte after receiving three different treatment regimens are evaluated in the second week

    Measured: two weeks

  2. Hemoglobin

    The increased levels of hemoglobin after receiving three different treatment regimens are evaluated in the fourth week

    Measured: four weeks

  3. Ferritin

    The increased levels of ferritin after receiving three different treatment regimens are evaluated in the eighth week

    Measured: eight weeks

  4. adverse events

    The incidence of adverse events every two weeks are assessed, the adverse events include bellyache, diarrhea, constipation, vomiting, nausea.

    Measured: every two weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2015 (estimated)
  2. Study start1 Jan 2016
  3. Primary completion31 Dec 2018
  4. Study completion31 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
440 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02631668
Sponsor's protocol ID
KY2015-270
Status last verified
Feb 2019
First submitted
14 Dec 2015
Last updated
25 Feb 2019
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Brugnara C. A hematologic "gold standard" for iron-deficient states? Clin Chem. 2002 Jul;48(7):981-2. No abstract available.

    PubMed 12089163
  • McCarley P. The KDOQI clinical practice guidelines and clinical practice recommendations for treating anemia in patients with chronic kidney disease: implications for nurses. Nephrol Nurs J. 2006 Jul-Aug;33(4):423-6, 445; quiz 427-8.

    PubMed 17002000
  • Okam MM, Koch TA, Tran MH. Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials. Haematologica. 2016 Jan;101(1):e6-7. doi: 10.3324/haematol.2015.129114. Epub 2015 Oct 30. No abstract available.

    PubMed 26518747
  • Joseph B, Ramesh N. Weekly dose of Iron-Folate Supplementation with Vitamin-C in the workplace can prevent anaemia in women employees. Pak J Med Sci. 2013 Jan;29(1):47-52. doi: 10.12669/pjms.291.3016.

    PubMed 24353506
  • Parveen N, Ahmad S, Shadab GG. Iron induced genotoxicity: attenuation by vitamin C and its optimization. Interdiscip Toxicol. 2014 Sep;7(3):154-8. doi: 10.2478/intox-2014-0021. Epub 2014 Dec 30.

    PubMed 26109893
  • Rocha Dda S, Capanema FD, Netto MP, de Almeida CA, Franceschini Sdo C, Lamounier JA. Effectiveness of fortification of drinking water with iron and vitamin C in the reduction of anemia and improvement of nutritional status in children attending day-care centers in Belo Horizonte, Brazil. Food Nutr Bull. 2011 Dec;32(4):340-6. doi: 10.1177/156482651103200405.

    PubMed 22590967
  • Li N, Zhao G, Wu W, Zhang M, Liu W, Chen Q, Wang X. The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia: A Randomized Clinical Trial. JAMA Netw Open. 2020 Nov 2;3(11):e2023644. doi: 10.1001/jamanetworkopen.2020.23644.

    PubMed 33136134

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing ferrous succinate and vitamin C and ferrous succinate in people with Anemia, Iron-Deficiency, run by Huashan Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hemoglobin (time frame: two weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02631668, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in